Search clinical trials for: empagliflozin (Jardiance) 25 mg

Total 831 results

University of Virginia
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes (EJB051)

Type2 Diabetes | Insulin Sensitivity

United States
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
University of Sao Paulo

Completed

Effect of Empagliflozin on Ventricular Repolarization. (EMPATHYHEART)

Diabetes Mellitus, Type 2 | Coronary Heart Disease | Arrythmia, Cardiac

Brazil
Vanderbilt University Medical Center

Completed

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Obesity | Pre-diabetes

United States
Isfahan University of Medical Sciences

Completed

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Diabetes Mellitus

Iran, Islamic Republic of
Shahid Beheshti University of Medical Sciences

Recruiting

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Kidney Transplant; Complications

Iran, Islamic Republic of
University Hospital, Basel, Switzerland
Centre Hospitalier Universitaire Vaudois; Luzerner Kantonsspital

Recruiting

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (EMPOWER)

Liver Failure | Hyponatremia | Kidney Failure | SIADH

Switzerland
University Hospital Inselspital, Berne

Completed

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Dumping Syndrome | Hypoglycemia, Reactive

Switzerland
Profil Institut für Stoffwechselforschung GmbH

Completed

Empagliflozin and Sympathetic Nerve Traffic

Type 2 Diabetes Mellitus

Germany
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (EmpaSema)

Type 2 Diabetes With Renal Manifestations

Denmark
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
University Hospital Inselspital, Berne
Boehringer Ingelheim; University of Bern

Completed

Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers (SWEETSTONE)

Kidney Stone

Switzerland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Karolinska Institutet
Karolinska University Hospital

Recruiting

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes (DiaSpax)

Type 2 Diabetes

Sweden
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Empagliflozin and Hepatic Glucose Metabolism

Hepatic Glucose Metabolism

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
Handok Inc.

Completed

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
Christian Schulze
Boehringer Ingelheim; Zentrum für Klinische Studien Jena

Completed

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

Acute Decompensated Heart Failure

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
Boehringer Ingelheim

Completed

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Healthy

Germany
Kasr El Aini Hospital

Completed

Empagliflozin in Patients With Glomerulonephritis

Proteinuria | Glomerulonephritis

Egypt
Boehringer Ingelheim

Completed

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
University of Catanzaro

Completed

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) (FIORE)

Type 2 Diabetes | Cardiovascular Risk Factor

Italy
Medical University of Lodz

Recruiting

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Chronic Kidney Disease stage3

Poland
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
Boehringer Ingelheim
Eli Lilly and Company

Active, not recruiting

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Heart Failure

Japan
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Seoul National University Bundang Hospital

Not yet recruiting

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Type 2 Diabetes | Metabolic-associated Fatty Liver Disease
Rambam Health Care Campus
Boehringer Ingelheim

Unknown

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients (ERA-HF)

Heart Failure | Diabetes Mellitus | Arrythmia
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Ain Shams University

Completed

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Pharmacokinetics | Pharmacogenomic

Egypt
The Deutsche Diabetes Forschungsgesellschaft e.V.
Novo Nordisk A/S; Boehringer Ingelheim; Federal Ministry of Health, Germany; German... and other collaborators

Recruiting

Combined Active Treatment in Type 2 Diabetes With NASH (COMBAT_T2_NASH)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Germany, Austria
Zydus Lifesciences Limited

Active, not recruiting

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
British University In Egypt

Completed

Pharmacokinetic Evaluation of Empagliflozin

Diabetes Mellitus
Boehringer Ingelheim

Recruiting

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Heart Failure

Korea, Republic of
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Asmaa Abdelfattah Elsayed

Completed

Follow-up of NAFLD Patients With MRI-PDFF

NAFLD | Diabetes Type 2

Egypt
Aristotle University Of Thessaloniki

Unknown

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics (PREHYPD)

Hypertension | Type II Diabetes

Greece
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
University Hospital, Basel, Switzerland
Boehringer Ingelheim

Recruiting

Empagliflozin for the Treatment of Postprandial Hypoglycemia (EmpHy)

Postprandial Hypoglycemia

Switzerland
Royal Perth Hospital

Recruiting

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Obesity | Type 2 Diabetes Mellitus | Metabolic Syndrome

Australia
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Type2 Diabetes Mellitus

India
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, United States, France, Germany, Italy, Argentina, Czechia, Vietnam, Peru, China, Philippines, Saudi Arabia, Taiwan, Australia, Austria, Canada, Japan, Malaysia, Poland, Thailand, Israel, Brazil, Finland, Greece, United Kingdom, Mexico and more
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden

Search clinical trials for: empagliflozin (Jardiance) 25 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations